Adding bedaquiline or delamanid to background regimen for treatment of multi-drug resistant tuberculosis: a cost-effectiveness analysis

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YOU, Joyce (The Chinese University of Hong Kong, School of Pharmacy, Shatin, Hong Kong SAR China)
  • Co-author(s): Wai-Ying Yip School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
    Joyce You
  • Abstract:


    A decision-analytic model including decision tree and Markov model was designed to simulate outcomes of MDR-TB with three options: BR, bedaquiline plus BR (B-BR) and delamanid plus BR (D-BR). Model time horizon was 10 years. Outcome measures were mortality rate, quality-adjusted life year (QALY) gain, and direct medical cost. Sensitivity..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login